Sugi Predict

Sugi Predict / Compounds / SCHEMBL18152671

SCHEMBL18152671

SCHEMBL18152671

Cc1cc(F)c(Br)cc1S(N)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ KDM1A O60341 2/20 0.41
▸ KDM1B Q8NB78 1/20 0.41
▸ CA2 P00918 5/20 0.40
▸ CA1 P00915 4/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ PDIA6 Q15084 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CA7 P43166 3/20 0.38
▸ CA4 P22748 2/20 0.38
▸ CA6 P23280 2/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA13 Q8N1Q1 2/20 0.38
▸ SOS1 Q07889 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PTGS1 P23219 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524948 0.88 POLB (0.41) KDM4EALDH1A1KDM1AKDM1BCA2
SCHEMBL8408242 0.85 KDM1A (0.40) KDM4EALDH1A1KDM1AKDM1BCA2
SCHEMBL8404542 0.85 KDM1A (0.40) KDM4EALDH1A1KDM1AKDM1BCA2
SCHEMBL20150026 0.85 KDM4E (0.45) KDM4EALDH1A1CA2CA1CA9
SCHEMBL1346797 0.83 CA2 (0.48) KDM4EALDH1A1KDM1AKDM1BCA2
SCHEMBL17203518 0.82 POLB (0.37) KDM1AKDM1BCA2CA1CA9
SCHEMBL20182618 0.81 POLB (0.53) KDM4EALDH1A1CA2CA1CA9
Hydrochloric Acid SCHEMBL28127294 0.81 BRD4 (0.37) KDM1AKDM1BCA2CA1CA9
SCHEMBL2773813 0.80 KDM4E (0.41) KDM4EALDH1A1KDM1AKDM1BCA2
SCHEMBL18668395 0.79 KDM4E (0.43) KDM4EALDH1A1CA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3606921-B1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. INVENTIVA (FR) 2022-06-01 — — EP disclosed
EP-3831383-A1 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-06-09 — — EP disclosed
EP-3283077-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2021-03-10 — — EP disclosed
US-10807982-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-10-20 — — US disclosed
US-10683289-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-06-16 — — US disclosed
US-10683289-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-06-16 — — US disclosed
US-20200115353-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA INVENTIVA (FR) 2020-04-16 — — US disclosed
US-20200071332-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-03-05 — — US disclosed
EP-3606921-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. Inventiva (FR) 2020-02-12 — — EP disclosed
CN-110709396-A Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma 伊文蒂瓦公司 2020-01-17 — — CN disclosed
US-20190337935-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2019-11-07 — — US disclosed
WO-2018185266-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. INVENTIVA (FR) 2018-10-11 — — WO disclosed
US-20180134710-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-05-17 — — US disclosed
US-9908885-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-03-06 — — US disclosed
EP-3283077-A2 BROMODOMAIN INHIBITOR Celgene Quanticel Research, Inc. (US) 2018-02-21 — — EP disclosed
US-20170050968-A1 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. 2017-02-23 — — US disclosed
WO-2016168682-A2 BROMODOMAIN INHIBITOR CELGENE QUANTICEL RESEARCH, INC. (US) 2016-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071332-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 KDM4E 137/4885ALDH1A1 3316/4885KDM1A 87/4885
US-10683289-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof BAD, AIFM1, BCL2 KDM4E 1757/4885ALDH1A1 1702/4885KDM1A 1675/4885
US-20170050968-A1 BROMODOMAIN INHIBITOR BRD3, BRPF3, EP300 KDM4E 133/4885ALDH1A1 3261/4885KDM1A 81/4885
US-10807982-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 KDM4E 137/4885ALDH1A1 3316/4885KDM1A 87/4885
US-20190337935-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF BAD, AIFM1, BCL2 KDM4E 1757/4885ALDH1A1 1702/4885KDM1A 1675/4885
US-20200115353-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA YAP1, TEAD2, TEAD1 KDM4E 1436/4885ALDH1A1 3397/4885KDM1A 1470/4885
US-20180134710-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 KDM4E 137/4885ALDH1A1 3316/4885KDM1A 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.